Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2014	Jul. 22, 2014
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q2
Entity Registrant Name	NeuroMetrix, Inc.
Entity Central Index Key	0001289850
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	NURO
Entity Common Stock, Shares Outstanding		7,944,257

Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 13,693,792	$ 9,195,753
Accounts receivable, net	532,837	390,922
Inventories	604,066	563,036
Prepaid expenses and other current assets	349,926	416,816
Total current assets	15,180,621	10,566,527
Fixed assets, net	180,411	229,313
Other long-term assets	674	923
Total assets	15,361,706	10,796,763
Current liabilities:
Accounts payable	534,532	322,896
Accrued compensation	811,155	386,004
Accrued expenses	977,189	870,196
Current portion of deferred revenue	49,713	68,812
Total current liabilities	2,372,589	1,647,908
Deferred revenue, net of current portion	11,239	15,277
Common stock warrants	5,367,565	1,938,603
Total liabilities	7,751,393	3,601,788
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized at June 30, 2014 and December 31, 2013: Convertible preferred stock; 11,083 and 4,438 shares designated at June 30, 2014 and December 31, 2013, respectively, and 6,440.216 and 0 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively	6	0
Common stock, $0.0001 par value; 50,000,000 shares authorized; 6,759,032 and 5,945,581 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively	676	595
Additional paid-in capital	157,617,019	153,806,460
Accumulated deficit	(150,007,388)	(146,612,080)
Total stockholders’ equity	7,610,313	7,194,975
Total liabilities and stockholders’ equity	$ 15,361,706	$ 10,796,763

Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	6,759,032	5,945,581
Common stock, shares outstanding	6,759,032	5,945,581
Convertible Preferred Stock [Member]
Preferred stock, shares authorized	11,083	4,438
Preferred stock, issued	6,440.216	0
Preferred stock, outstanding	6,440.216	0

Statements of Operations (USD $)	3 Months Ended		6 Months Ended
Statements of Operations (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues	$ 1,343,770	$ 1,160,472	$ 2,675,307	$ 2,561,926
Cost of revenues	655,337	501,161	1,270,418	1,070,945
Gross profit	688,433	659,311	1,404,889	1,490,981
Operating expenses:
Research and development	1,464,834	913,847	2,328,551	1,987,266
Sales and marketing	694,664	880,218	1,140,880	1,660,059
General and administrative	1,148,278	992,160	2,295,035	2,225,754
Total operating expenses	3,307,776	2,786,225	5,764,466	5,873,079
Loss from operations	(2,619,343)	(2,126,914)	(4,359,577)	(4,382,098)
Interest income	990	1,394	2,026	3,163
Warrants offering costs	(27,618)	(376,306)	(27,618)	(376,306)
Change in fair value of warrant liability	475,261	1,155,996	989,861	1,155,996
Net loss	$ (2,170,710)	$ (1,345,830)	$ (3,395,308)	$ (3,599,245)
Net loss per common share applicable to common stockholders, basic and diluted (See Note 3, Net Loss per Common Share)	$ (0.85)	$ (0.92)	$ (1.06)	$ (1.97)
Weighted average number of common shares outstanding, basic and diluted	6,002,330	2,299,463	5,966,929	2,215,658

Statements of Cash Flows (USD $)	6 Months Ended
Statements of Cash Flows (USD $)	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:
Net loss	$ (3,395,308)	$ (3,599,245)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	66,293	79,299
Stock-based compensation	137,164	96,107
Inventory charges	0	77,642
Warrants offering cost	27,618	376,306
Change in fair value of warrant liability	(989,861)	(1,155,996)
Changes in operating assets and liabilities:
Accounts receivable	(141,915)	4,388
Inventories	(41,030)	2,940
Prepaid expenses and other current assets	65,028	156,888
Accounts payable	211,636	(48,863)
Accrued expenses and compensation	636,551	383,263
Deferred revenue, deferred costs, and other	(21,028)	(35,890)
Net cash used in operating activities	(3,444,852)	(3,663,161)
Cash flows from investing activities:
Purchases of fixed assets	(17,392)	(15,968)
Net cash used in investing activities	(17,392)	(15,968)
Cash flows from financing activities:
Net proceeds from issuance of stock and equity	7,960,283	4,576,732
Payments on capital lease	0	(10,646)
Net cash provided by financing activities	7,960,283	4,566,086
Net increase in cash and cash equivalents	4,498,039	886,957
Cash and cash equivalents, beginning of period	9,195,753	8,699,478
Cash and cash equivalents, end of period	13,693,792	9,586,435
Supplemental disclosure of cash flow information:
Common stock issued to settle incentive compensation obligation	104,402	285,296
Warrants issued under Securities Purchase Agreement recorded as a non-current liability	$ 4,418,824	$ 4,011,205

Business and Basis of Presentation

6 Months Ended

Jun. 30, 2014

Accounting Policies [Abstract]

Business and Basis of Presentation

1.	Business and Basis of Presentation

Our Business-An Overview

NeuroMetrix, Inc., or the Company, a Delaware corporation, was founded in June 1996. The Company is an innovative health-care company that develops wearable medical technology and point-of-care diagnostic tests to help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The Company believes that there are large and important unmet needs in the treatment of diabetic neuropathies and adjacent forms of chronic pain such as fibromyalgia, post herpetic neuropathy (shingles), and conditions with both chronic pain and disturbed sleep such as restless leg syndrome. With substantial experience in medical devices to measure and alter peripheral nerve function, the Company believes it is well positioned to address these unmet needs through the development of novel proprietary medical devices. Accordingly, the Company has a major focus on developing and marketing medical devices for diabetic neuropathies. The Company has over a decade of experience in neuropathy detection starting with approval in 1998 by the United States Food and Drug Administration, or FDA, of the NC-stat System, a point-of-care device for the performance of general purpose nerve conduction studies.

In 2013 the Company launched the SENSUS™ Pain Management System, or SENSUS, a wearable transcutaneous electrical nerve stimulator indicated for management of chronic pain, and is the only device cleared by the FDA for use during sleep. It markets SENSUS to physicians managing patients with painful diabetic neuropathy and other forms of chronic pain. The Company also markets the NC-stat^® DPNCheck^® device, which is a fast, accurate, and quantitative nerve conduction test used to evaluate systemic neuropathies such as diabetic peripheral neuropathy, or DPN. NC-stat DPNCheck is designed to be used by physicians and other clinicians at the point-of-care to objectively detect, stage, and monitor DPN. The Company’s historical neurodiagnostic business is based on the ADVANCE™ NCS/EMG System, or the ADVANCE System, which is a comprehensive platform for the performance of traditional nerve conduction studies and invasive electromyography procedures and which is primarily used in physician offices and clinics. While the ADVANCE System contributes to the Company’s revenues, the Company is not actively managing the ADVANCE business for growth.

On June 24, 2014, the Company entered into a Securities Purchase Agreement with a single institutional investor providing for the issuance of common stock, convertible preferred stock and warrants to purchase common stock, which is referred to as the 2014 Offering. The Company received net proceeds of $7.9 million from the 2014 Offering. See Note 9, Stockholders’ Equity, for additional details.

The Company held cash and cash equivalents of $13.7 million as of June 30, 2014. The Company believes that these resources and the cash to be generated from expected product sales will be sufficient to meet its projected operating requirements for at least the next twelve months. The Company continues to face significant challenges and uncertainties and, as a result, the Company’s available capital resources may be consumed more rapidly than currently expected due to (a) unanticipated decreases in sales of the Company’s products and the uncertainty of future revenues from the Company’s new products; (b) changes the Company may make to the business that affect ongoing operating expenses; (c) changes the Company may make in its business strategy; (d) regulatory developments affecting the Company’s existing products and delays in the FDA approval process for products under development; (e) changes in the Company’s research and development spending plans; and (f) other items affecting the Company’s forecasted level of expenditures and use of cash resources. Accordingly, the Company will need to raise additional funds to support its future operating and capital needs beyond the next twelve months. The Company may attempt to obtain additional funding through public or private financing, collaborative arrangements with strategic partners, or through additional credit lines or other debt financing sources to increase the funds available to fund operations. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity or debt securities to raise additional funds, its existing stockholders may experience dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies, or grant licenses on terms that are not favorable to the Company. Without additional funds, the Company may be forced to delay, scale back or eliminate some of its sales and marketing efforts, research and development activities, or other operations and potentially delay product development in an effort to provide sufficient funds to continue its operations. If any of these events occur, the Company’s ability to achieve its development and commercialization goals would be adversely affected.

Unaudited Interim Financial Statements

The accompanying unaudited balance sheet as of June 30, 2014, unaudited statements of operations for the quarters and six months ended June 30, 2014 and 2013 and the unaudited statements of cash flows for the six months ended June 30, 2014 and 2013 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair statement of the Company’s financial position and operating results. Operating results for the quarter ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, or the SEC, on February 24, 2014 (File No. 001-33351), or the Company’s 2013 Form 10-K. The accompanying balance sheet as of December 31, 2013 has been derived from audited financial statements prepared at that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America.

Revenues

The Company recognizes revenue when the following criteria have been met: persuasive evidence of an arrangement exists, delivery has occurred and risk of loss has passed, the seller’s price to the buyer is fixed or determinable, and collection is reasonably assured.

Revenues associated with the sale of the ADVANCE devices to customers and distributors are recognized upon shipment, provided that the selling price is fixed or determinable, persuasive evidence of an arrangement exists, collection of receivables is reasonably assured, product returns are reasonably estimable, and no continuing obligations exist. The revenues from the sale of an ADVANCE communication hub together with access to NeuroMetrix information systems are considered one unit of accounting and deferred and recognized on a straight-line basis over the estimated period of time that the Company provides the service associated with the information systems of three years. The resulting deferred revenue and deferred costs are presented as separate line items on the accompanying balance sheet. Revenues related to extended service agreements for the devices are recognized ratably over the term of the extended service agreement.

Revenues associated with the sale of the SENSUS and NC-stat DPNCheck devices are recognized upon shipment, provided that the selling price is fixed or determinable, persuasive evidence of an arrangement exists, collection of receivables is reasonably assured, product returns are reasonably estimable, and no continuing obligations exist.

Revenues also include sales of consumables, including single use nerve specific electrodes and other accessories. These revenues are recognized upon shipment provided that the selling price is fixed or determinable, persuasive evidence of an arrangement exists, collection of receivables is reasonably assured, and product returns are reasonably estimable.

When multiple elements are contained in a single arrangement, the Company allocates revenue between the elements based on their relative selling prices. The Company determines selling price using vendor specific objective evidence, or VSOE, if it is available, third-party evidence, or TPE, if VSOE is not available, and best estimate of selling price, or BESP, if neither VSOE nor TPE are available. The Company generally expects that it will not be able to establish TPE due to the nature of the markets in which it competes, and, as such, it will typically determine selling price using VSOE or if not available, BESP. The objective of BESP is to determine the selling price of a deliverable on a standalone basis. The Company’s determination of BESP involves a weighting of several factors based on the specific facts and circumstances of an arrangement. Specifically, the Company considers the cost to produce the deliverable, the anticipated margin on that deliverable, the selling price and profit margin for similar parts, its ongoing pricing strategy, the value of any enhancements that have been built into the deliverable, and the characteristics of the varying markets in which the deliverable is sold.

Revenue recognition involves judgments, including assessments of expected returns and expected customer relationship periods. The Company analyzes various factors, including a review of specific transactions, its historical returns, average customer relationship periods, customer usage, customer balances, and market and economic conditions. Changes in judgments or estimates on these factors could materially impact the timing and amount of revenues and costs recognized. Should market or economic conditions deteriorate, the Company’s actual return or bad debt experience could exceed its estimate.

Certain product sales are made with a 30-day right of return. Since the Company can reasonably estimate future returns, it recognizes revenues associated with product sales that contain a right of return upon shipment and at the same time it records a sales return reserve, which reduces revenue and accounts receivable by the amount of estimated returns.

During the quarter and six months ended June 30, 2014 one customer accounted for 13% and 12% of total revenue, respectively. No customers exceeded 10% in prior periods.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.

Recent Accounting Pronouncements

In May 2014, the FASB and the International Accounting Standards Board (“IASB”) jointly issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), a comprehensive new revenue recognition standard that will supersede nearly all existing revenue recognition guidance. The objective of ASU 2014-09 is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 will be effective for the first quarter of 2017. An entity can elect to adopt ASU 2014-09 using one of two methods, either full retrospective adoption to each prior reporting period, or recognizing the cumulative effect of adoption at the date of initial application. The Company is in the process of evaluating the new standard and does not know the effect, if any, ASU 2014-09 will have on the Consolidated Financial Statements or which adoption method will be used.

Comprehensive Loss

6 Months Ended

Jun. 30, 2014

Stockholders' Equity Note [Abstract]

Comprehensive Loss

2.	Comprehensive Loss

For the quarters ended June 30, 2014 and 2013, the Company had no components of other comprehensive income or loss other than net loss itself.

Business and Basis of Presentation - Additional Information (Detail) (USD $)	1 Months Ended		6 Months Ended				3 Months Ended	6 Months Ended
	Jun. 24, 2014	Jun. 04, 2013	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012	Jun. 30, 2014 Customer One	Jun. 30, 2014 Customer One
Organization And Basis Of Presentation [Line Items]
Cash and cash equivalents			$ 13,693,792	$ 9,195,753	$ 9,586,435	$ 8,699,478
Entity Date Of Incorporation			1996-06
Concentration risk, percentage							13.00%	12.00%
Proceeds from Issuance or Sale of Equity, Total	$ 7,900,000	$ 4,500,000

Comprehensive Loss - Additional Information (Detail) (USD $)	3 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Other Comprehensive Income Loss [Line Items]
Other comprehensive income (loss), net of tax	$ 0	$ 0

Inventories (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Inventory Disclosure [Line Items]
Purchased components	$ 220,437	$ 205,320
Finished goods	383,629	357,716
Inventories	$ 604,066	$ 563,036

Accrued Compensation and Expenses - Additional Information (Detail) (USD $)	3 Months Ended
	Jun. 30, 2014
Accrued Compensation and Expenses [Line Items]
Severance Costs	$ 303,000

Accrued Expenses (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Schedule of Accrued Liabilities [Line Items]
Technology fees	$ 450,000	$ 450,000
Professional services	319,651	263,642
Clinical study obligations	37,000	51,424
Sales taxes	32,628	32,688
Other	137,910	72,442
Accrued expenses	$ 977,189	$ 870,196

Commitments and Contingencies - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2013
Commitments and Contingencies Disclosure [Line Items]
Lease expiration date	Mar. 31, 2015
January 2014 through March 2015
Commitments and Contingencies Disclosure [Line Items]
Base rent, per month	$ 52,917

Fair Value Measurements - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Fair Value Disclosures [Line Items]
Common stock warrants liability	$ 5,367,565	$ 1,938,603

Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Assets:
Cash equivalents	$ 12,853,692	$ 3,926,600
Total	12,853,692	3,926,600
Liabilities:
Common stock warrants	5,367,565	1,938,603
Total	5,367,565	1,938,603
Fair Value, Inputs, Level 1
Assets:
Total	12,853,692	3,926,600
Liabilities:
Total	0	0
Fair Value, Inputs, Level 1 \| Fair Value, Measurements, Recurring
Assets:
Cash equivalents	12,853,692	3,926,600
Liabilities:
Common stock warrants	0	0
Fair Value, Inputs, Level 2
Assets:
Total	0	0
Liabilities:
Total	0	0
Fair Value, Inputs, Level 2 \| Fair Value, Measurements, Recurring
Assets:
Cash equivalents	0	0
Liabilities:
Common stock warrants	0	0
Fair Value, Inputs, Level 3
Assets:
Total	0	0
Liabilities:
Total	5,367,565	1,938,603
Fair Value, Inputs, Level 3 \| Fair Value, Measurements, Recurring
Assets:
Cash equivalents	0	0
Liabilities:
Common stock warrants	$ 5,367,565	$ 1,938,603

Black-Scholes Inputs to Warrant Liability Valuation (Detail) (USD $)			6 Months Ended		12 Months Ended
	Jun. 24, 2014	Jun. 04, 2013	Jun. 30, 2014 2014 Offering	Jun. 30, 2014 2013 Offering	Dec. 31, 2013 2013 Offering
Stock Price	$ 2.04	$ 2.095	$ 1.94	$ 1.94	$ 2.92
Exercise price			$ 2.04	$ 2.00	$ 2.00
Expected volatility			68.27%	73.16%	67.60%
Risk free interest rate			1.62%	1.25%	1.71%
Expected Term			5 years	3 years 11 months	4 years 5 months
Dividends			0.00%	0.00%	0.00%

Summary of changes in fair value of company's level 3 financial liabilities (Details) (Warrants, USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Summary of changes in the fair value [Line Items]
Balance	$ 1,938,603	$ 0
Initial fair value of warrants at issuance in June	4,418,823	4,011,205
Change in fair value of warrant liability	(989,861)	289,657
Reclassification of liability to additional paid-in capital upon exercise of warrants	0	(2,362,259)
Balance	5,367,565	1,938,603
2014 Offering
Summary of changes in the fair value [Line Items]
Balance	0	0
Initial fair value of warrants at issuance in June	4,418,823	0
Change in fair value of warrant liability	(150,980)	0
Reclassification of liability to additional paid-in capital upon exercise of warrants	0	0
Balance	4,267,843	0
2013 Offering
Summary of changes in the fair value [Line Items]
Balance	1,938,603	0
Initial fair value of warrants at issuance in June	0	4,011,205
Change in fair value of warrant liability	(838,881)	289,657
Reclassification of liability to additional paid-in capital upon exercise of warrants	0	(2,362,259)
Balance	$ 1,099,722	$ 1,938,603

Credit Facility - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014
Line of Credit Facility [Line Items]
Revolving credit facility, maximum borrowing capacity	$ 2,500,000
Credit Facility expiration date	Jan. 15, 2015
Credit Facility limit restricted to support letter of credit	225,000
Line of credit facility, remaining borrowing capacity	$ 2,275,000
Prime Rate
Line of Credit Facility [Line Items]
Interest rate over prime rate	0.50%